An anti-GD2 aptamer-based bifunctional spherical nucleic acid nanoplatform for synergistic therapy targeting MDM2 for retinoblastoma

Wang, Shijing; Zhao, Yan; Yao, Fei; Wei, Pengxue; Ma, Lan; Zhang, Shaochong

doi:10.1016/j.biopha.2024.116437

Cited by 2 publications

(3 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Specifically, nucleic-acid-based NPs are also a point of discussion. Although not explored extensively in retinoblastoma, Wang et al (2024) recently experimented with spherical nucleic acid (SNA) NPs to deliver siRNA. These SNA NPs with a dense DNA shell contain aptamers, targeting disialoganglioside (GD2) positive RB cells, and are loaded with siRNA and the inhibitor NVP-CGM097.…”

Section: Future Perspectivesmentioning

confidence: 99%

“…However, in vivo studies on Y79 and WERI-RB-1 xenograft nude mouse models demonstrated that the SNA NPs caused less retinal damage than melphalan. Retinal thickness was noticeably reduced by melphalan, and the thickness only recovered on day 21 compared to a milder reduction and rapid recovery on day 14 in the SNA NP groups [94]. Compared to siRNA, DNA therapeutic agents are more stable and have a higher degradation resistance, making them potential candidates for RB treatment [95].…”

Section: Future Perspectivesmentioning

confidence: 99%

See 1 more Smart Citation

Advancements in Nanosystems for Ocular Drug Delivery: A Focus on Pediatric Retinoblastoma

Wu,

Wang,

Anderson

et al. 2024

Molecules

View full text Add to dashboard Cite

The eye’s complex anatomical structures present formidable barriers to effective drug delivery across a range of ocular diseases, from anterior to posterior segment pathologies. Emerging as a promising solution to these challenges, nanotechnology-based platforms—including but not limited to liposomes, dendrimers, and micelles—have shown the potential to revolutionize ophthalmic therapeutics. These nanocarriers enhance drug bioavailability, increase residence time in targeted ocular tissues, and offer precise, localized delivery, minimizing systemic side effects. Focusing on pediatric ophthalmology, particularly on retinoblastoma, this review delves into the recent advancements in functionalized nanosystems for drug delivery. Covering the literature from 2017 to 2023, it comprehensively examines these nanocarriers’ potential impact on transforming the treatment landscape for retinoblastoma. The review highlights the critical role of these platforms in overcoming the unique pediatric eye barriers, thus enhancing treatment efficacy. It underscores the necessity for ongoing research to realize the full clinical potential of these innovative drug delivery systems in pediatric ophthalmology.

show abstract

Section: Future Perspectivesmentioning

confidence: 99%

Section: Future Perspectivesmentioning

confidence: 99%

Advancements in Nanosystems for Ocular Drug Delivery: A Focus on Pediatric Retinoblastoma

Wu,

Wang,

Anderson

et al. 2024

Molecules

View full text Add to dashboard Cite

show abstract

“…P53 plays a critical protective role in ophthalmic diseases by monitoring cellular DNA damage and stress signals. When retinal cells undergo photic damage, hypoxia, or metabolic stress, P53 is swiftly activated to induce cell cycle arrest, thereby allowing time for DNA repair ( 63 ). If the damage is too severe, P53 initiates the programmed cell death process to prevent the proliferation of damaged cells and potential tumor formation.…”

Section: Characteristics Of Ferroptosismentioning

confidence: 99%

Ferroptosis: a novel mechanism of cell death in ophthalmic conditions

Yang,

Lin,

Han

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

Ferroptosis, a new type of programmed cell death proposed in recent years, is characterized mainly by reactive oxygen species and iron-mediated lipid peroxidation and differs from programmed cell death, such as apoptosis, necrosis, and autophagy. Ferroptosis is associated with a variety of physiological and pathophysiological processes. Recent studies have shown that ferroptosis can aggravate or reduce the occurrence and development of diseases by targeting metabolic pathways and signaling pathways in tumors, ischemic organ damage, and other degenerative diseases related to lipid peroxidation. Increasing evidence suggests that ferroptosis is closely linked to the onset and progression of various ophthalmic conditions, including corneal injury, glaucoma, age-related macular degeneration, diabetic retinopathy, retinal detachment, and retinoblastoma. Our review of the current research on ferroptosis in ophthalmic diseases reveals significant advancements in our understanding of the pathogenesis, aetiology, and treatment of these conditions.

show abstract

An anti-GD2 aptamer-based bifunctional spherical nucleic acid nanoplatform for synergistic therapy targeting MDM2 for retinoblastoma

Cited by 2 publications

References 47 publications

Advancements in Nanosystems for Ocular Drug Delivery: A Focus on Pediatric Retinoblastoma

Advancements in Nanosystems for Ocular Drug Delivery: A Focus on Pediatric Retinoblastoma

Ferroptosis: a novel mechanism of cell death in ophthalmic conditions

Contact Info

Product

Resources

About